VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel small molecule product candidates targeting Toll-like receptor 8 (TLR8) for cancer.

from http://www.ventirx.com/about/index.html

Publications show all

VentiRx Pharmaceuticals has published 13 articles.

Patents show all

55Applications33Issued

Clinical Trials show all

2Phase 12Phase 1/Phase 22Phase 2

SEC Filings show all

D4

SEC Form D Funding Events

DateOfferedSoldType
2014-09-30$15,000,000$15,000,000Equity, Option to Acquire, Security to be Acquired
2014-09-23$53,102,414$50,602,514Equity
2012-03-08$25,000,002$18,750,001Equity
2007-03-22UnknownUnknownOther (Paper Filing)

Key Executives

  • Robert M. Hershberg, M.D., Ph.D.
    Executive Officer, Director
  • Patrick Heron
    Director
  • Nicole Vitullo
    Director
  • Steven Gillis, Ph.D.
    Director
  • Elliot Grossbard, M.D.
    Director
  • Atul Saran
    Director
  • Kent Snyder
    Director
  • Ron Laufer
    Director
  • Kathleen Fanning
    Executive Officer